Literature DB >> 10411096

Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma.

A Huang1, P D Fone, R Gandour-Edwards, R W White, R K Low.   

Abstract

PURPOSE: To investigate the incidence, extent, and distribution of bcl-2 protein expression in human renal cell carcinomas.
MATERIALS AND METHODS: Using immunohistochemical tissue staining techniques, bcl-2 protein expression was analyzed in archival nephrectomy specimens removed for renal cell carcinoma or trauma and in 3 renal cell carcinoma cell lines.
RESULTS: Normal kidneys demonstrated bcl-2 immunopositivity primarily within the cytoplasm of distal tubule cells. Only rare and minor staining of the proximal tubular cells, thought to be the origin of renal cell carcinoma, was noted in histologically normal controls and areas adjacent to tumor. In contrast, bcl-2 protein expression was demonstrated in 70% of renal cell carcinomas and in all 3 experimental cell lines.
CONCLUSIONS: Bcl-2 is a proto-oncogene known to regulate apoptosis (programmed cell death). Bcl-2 protein is overexpressed in the majority of renal cell carcinomas examined. Bcl-2 overexpression may have a role in tumorigenesis and may explain the relative resistance of renal cell carcinoma to chemotherapeutic agents and to radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411096

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  IL-37 mediates the antitumor activity in renal cell carcinoma.

Authors:  Yazhuo Jiang; Yili Wang; Liang Liang; Yang Gao; Juan Chen; Yi Sun; Yongyi Cheng; Yonggang Xu
Journal:  Med Oncol       Date:  2015-10-13       Impact factor: 3.064

2.  The relationship of expression of bcl-2, p53, and proliferating cell nuclear antigen (PCNA) to cell proliferation and apoptosis in renal cell carcinoma.

Authors:  Zhaohui Zhu; Shian Xing; Ping Cheng; Guosheng Li; Yu Yang; Fuqing Zeng; Gongcheng Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

3.  Targeted therapy in renal cancer.

Authors:  Tanya B Dorff; Amir Goldkorn; David I Quinn
Journal:  Ther Adv Med Oncol       Date:  2009-11       Impact factor: 8.168

4.  STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.

Authors:  A Horiguchi; T Asano; K Kuroda; A Sato; J Asakuma; K Ito; M Hayakawa; M Sumitomo; T Asano
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

5.  Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.

Authors:  Henry Zall; Arnim Weber; Robert Besch; Niko Zantl; Georg Häcker
Journal:  Mol Cancer       Date:  2010-06-24       Impact factor: 27.401

6.  Effect of different doses of monosodium glutamate on the thyroid follicular cells of adult male albino rats: a histological study.

Authors:  Hanaa A Khalaf; Eetmad A Arafat
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

7.  NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues.

Authors:  Ibrahim Meteoglu; Ibrahim H Erdogdu; Nezih Meydan; Muhan Erkus; Sabri Barutca
Journal:  J Exp Clin Cancer Res       Date:  2008-10-19

8.  Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients.

Authors:  T Itoi; K Yamana; V Bilim; K Takahashi; F Tomita
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

9.  Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas.

Authors:  J D Kelly; J Dai; P Eschwege; J S Goldberg; B P Duggan; K E Williamson; N H Bander; D M Nanus
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

Review 10.  Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway.

Authors:  Ramy F Youssef; Nicholas G Cost; Oussama M Darwish; Vitaly Margulis
Journal:  Arab J Urol       Date:  2012-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.